8-KEarnings & ResultsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Jan 28, 2010)

Filed January 28, 2010For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K on January 28, 2010, to report its financial results for the fourth quarter and full year of 2009. This filing primarily serves to furnish the accompanying press release and supplemental information to the SEC, making these details publicly available. Investors should review the provided press release (Exhibit 99.1) and supplemental data (Exhibit 99.2) for specific financial performance, operational updates, and forward-looking statements related to the company's business during that period. The key takeaway for investors is the availability of the Q4 and full-year 2009 financial results. While the 8-K itself does not contain the detailed financial figures, it directs stakeholders to the official press release and website disclosures for comprehensive information. This includes any discussions of revenue, earnings per share, product performance, and strategic initiatives that were highlighted at the time of the announcement.

Key Highlights

  • 1BMY filed an 8-K on January 28, 2010, announcing its Q4 and full-year 2009 financial results.
  • 2The filing includes a press release (Exhibit 99.1) with the detailed financial results.
  • 3Supplemental information is also provided via Exhibit 99.2, available on the company's website.
  • 4This report serves as a notification and public dissemination of the company's financial performance for the stated periods.
  • 5Investors should refer to the exhibits for specific financial data and operational commentary.
  • 6The 8-K itself does not contain the financial figures but directs to their sources.

Frequently Asked Questions

The primary purpose of this 8-K filing is to officially announce and furnish Bristol-Myers Squibb Company's financial results for the fourth quarter and the full twelve months of 2009. It makes the company's press release and supplemental financial information publicly available through the SEC.

The actual financial results are not detailed within the 8-K filing itself. Investors need to refer to Exhibit 99.1, which is the press release dated January 28, 2010, and Exhibit 99.2, which contains supplemental information posted on the company's website (www.bms.com).

Based on the provided text, this 8-K filing is specifically focused on Item 2.02, which pertains to Results of Operations and Financial Condition. It primarily serves to disseminate the financial performance for Q4 and FY 2009. No other material events are explicitly mentioned within this filing excerpt.

The 8-K filing was signed by Sandra Leung, who holds the title of Senior Vice President, General Counsel, and Corporate Secretary for Bristol-Myers Squibb Company.